Phase 2 N=71 Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Unresectable or Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 28.9 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis
Primary: Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis
Phase 2 N=147 A Study in the Treatment of Osteoarthritis Knee Pain
Osteoarthritis Knee Pain
Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score From Electronic Diary at 5 Weeks — -2.05; -2.10; -2.09 units on a scale
Phase 2 N=19 Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Kidney Cancer
Primary: Progression-free Survival at 3 Months — 2.9 months
Phase 2 N=325 Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
End-stage Renal Disease
Primary: F2-isoprostane (F2-iso) — 0.077; 0.073 ng/ml — p=>0.05
Phase 2 N=338 Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Phase 2 N=98 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Stable Coronary Artery Disease
Primary: Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus…
Phase 2 N=548 A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18…
Phase 2 N=88 A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) of Groups by FDG Response at Day 56 — 28.1; 12.1 weeks — p=0.017
Phase 2 N=373 A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 Response (ACR20) — 20; 15; 17; 34 Participants
Phase 2 N=155 Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
Stroke · Muscle Spasticity · Motor Neuron Disease
Primary: Change From Baseline in Forced Vital Capacity (FVC) — 2.889; 3.068; 2.923; 0.057 Liters of air
Phase 2 N=181 Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Breast Neoplasm
Primary: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to…
Phase 2 N=90 A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
Respiratory Distress Syndrome, Adult · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8 — 43; -241 pg/mL — p=0.37
Phase 2 N=11 Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Change in Rickets Severity From Baseline to Week 24, Based on Assessment of Skeletal Radiographs Using Radiologic Global Impression of Change (RGI-C) — 2.00 Units on a…
Phase 2 N=18 Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
Respiratory Tract Diseases · Lung Diseases · Lung Diseases, Interstitial
Primary: Minimal/no Progression (1 yr) by High Resolution Computed Tomography (HRCT) & Pulmonary Function — 12 Participants